Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan 23, 2024--
Source: eagletribune.com
Jeremy Oconnell News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jeremy Oconnell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jeremy Oconnell Today - Breaking & Trending Today
Harnessing the potential of secretomes in age-related diseases
Juvena founder on how secreted proteins are breathing new life into biologics development for age-related diseases.
Source: longevity.technology
With Secreted Proteins Map, Juvena Finds Path to $41M for New Regenerative Meds
Juvena Therapeutics is developing secreted protein drugs built on new knowledge gleaned from proprietary technology that maps these proteins and the tissues in the body where they offer a regenerative effect. The startup’s lead program is in development for the muscle disorder myotonic dystrophy type 1.
Source: medcitynews.com
Juvena Therapeutics Raises $41M in Series A Funding
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Source: finsmes.com